iCAD Corp (ICAD) - Gunggung Aset Perusahaan

iCAD, Inc. (ICAD) develops AI tools to combat oncology. The market trend visualized in monetary format on GURU.Markets, which stands at 39.95, highlights the impact of geopolitical conflicts on component logistics and patent protection. The business relies on cloud services with high customer loyalty, although equipment procurement is limited by center budgets. Management aims to implement breast cancer diagnostics in clinics via a subscription system.

To isolate the fundamental stability of iCAD, Inc. (ICAD) from market noise, the sum of liabilities and equity is reverse-calculated via ROA, allowing for an assessment of the business's real resource potential. Analyzing fluctuations in total capital and liabilities reveals hidden tail-risk drawdown, particularly as geopolitical fragmentation and medical data sovereignty limit the expansion of AI cancer diagnostic systems.